Clinical impact of post-progression survival in patients with locally advanced non-small cell lung cancer after chemoradiotherapy

被引:0
|
作者
Imai, Hisao [1 ,2 ]
Kobayashi, Daijiro [3 ]
Kaira, Kyoichi [2 ]
Kawashima, Sayaka [4 ]
Masubuchi, Ken [1 ]
Murata, Masumi [3 ]
Ebara, Takeshi [3 ,5 ]
Kitamoto, Yoshizumi [3 ]
Minato, Koichi [1 ]
机构
[1] Gunma Prefectural Canc Ctr, Div Resp Med, 617-1 Takahayashinishi, Ota, Gunma 3738550, Japan
[2] Saitama Med Univ, Comprehens Canc Ctr, Int Med Ctr, Dept Resp Med, Hidaka, Saitama, Japan
[3] Gunma Prefectural Canc Ctr, Div Radiat Oncol, Ota, Gunma, Japan
[4] Gunma Prefectural Canc Ctr, Div Pharm, Ota, Gunma, Japan
[5] Kyorin Univ, Sch Med, Dept Radiat Oncol, Mitaka, Tokyo, Japan
关键词
chemoradiotherapy; Glasgow prognostic score; locally advanced non-small cell lung cancer; overall survival; post-progression survival; progression-free survival; GLASGOW PROGNOSTIC SCORE; SURROGATE END-POINTS; PHASE-III TRIAL; POSTPROGRESSION SURVIVAL; PERFORMANCE STATUS; TUMOR RESPONSE; CHEMOTHERAPY; THERAPY; METASTASIS; EFFICACY;
D O I
10.2478/raon-2022.0006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. The efficacy of first-line chemoradiotherapy for overall survival (OS) might be confounded by the subsequent treatments in patients with locally advanced non-small cell lung cancer (NSCLC). In this study, we assessed the associations of progression-free survival (PFS) and post-progression survival (PPS) with OS after chemoradiotherapy for locally advanced NSCLC using patient-level data. Patients and methods. Between January 2011 and December 2018, 45 patients with locally advanced NSCLC who had received first-line chemoradiotherapy and in whom recurrence occurred were analysed. The associations of PFS and PPS with OS were analysed at the individual level. Results. Linear regression and Spearman rank correlation analyses revealed that PPS was strongly correlated with OS (r = 0.72, p < 0.05, R 2 = 0.54), whereas PFS was moderately correlated with OS (r = 0.58, p < 0.05, R-2 = 0.34). The Glasgow prognostic score and liver metastases at recurrence were significantly associated with PPS (p < 0.001). Conclusions. The current analysis of individual-level data of patients treated with first-line chemoradiotherapy implied that PPS had a higher impact on OS than PFS in patients with locally advanced NSCLC. Additionally, current perceptions indicate that treatment beyond progression after first-line chemoradiotherapy might strongly affect OS.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Post-Progression Survival after EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations
    Kogure, Yoshihito
    Saka, Hideo
    Oki, Masahide
    Saito, Toshiki I.
    Ahmed, Shimaa Nour Moursi
    Kitagawa, Chiyoe
    Imaizumi, Kazuyoshi
    PLOS ONE, 2015, 10 (08):
  • [22] Post-Progression Survival in Patients with Non-Small Cell Lung Cancer with Clinically Acquired Resistance to Gefitinib
    Kim, Hyojeong
    Yun, Tak
    Lee, Young Joo
    Han, Ji-Youn
    Kim, Heung Tae
    Lee, Geon Kook
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2013, 28 (11) : 1595 - 1602
  • [23] Chemoradiotherapy in Elderly Patients with Locally Advanced Non-Small Cell Lung Cancer
    Linhas, Ana
    Dias, Margarida
    Campainha, Sergio
    Conde, Sara
    Barroso, Ana
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S857 - S858
  • [24] The Impact of Radiation Pneumonitis on Prognosis of Patients with Locally Advanced Non-Small Cell Lung Cancer Treated with Chemoradiotherapy
    Akita, T.
    Baba, K.
    Tanaka, H.
    Fujioka, I.
    Suzuki, S.
    Tabe, C.
    Shiratori, T.
    Ishioka, Y.
    Itoga, M.
    Taima, K.
    Yokouchi, J.
    Hasegawa, Y.
    Takanashi, S.
    Tasaka, S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S636 - S636
  • [25] Individual-level data on the relationships of progression-free survival and post-progression survival with overall survival in patients with advanced non-squamous non-small cell lung cancer patients who received second-line chemotherapy
    Hisao Imai
    Keita Mori
    Akira Ono
    Hiroaki Akamatsu
    Tetsuhiko Taira
    Hirotsugu Kenmotsu
    Tateaki Naito
    Kyoichi Kaira
    Haruyasu Murakami
    Masahiro Endo
    Takashi Nakajima
    Toshiaki Takahashi
    Medical Oncology, 2014, 31
  • [26] Early administration of durvalumab after chemoradiotherapy increased risk of pneumonitis in patients with locally advanced non-small cell lung cancer
    Harada, Daijiro
    Shimonishi, Atsushi
    Saeki, Kazuhiko
    Ninomiya, Takashi
    Kanzaki, Hiromitsu
    Nagasaki, Kei
    Ogura, China
    Tsutsui, Yoko
    Kojin, Kazuhiro
    Hamamoto, Yasushi
    Kozuki, Toshiyuki
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2023, 19 (02) : E111 - E117
  • [27] Predictors of Post-chemoradiotherapy Pulmonary Complication in Locally Advanced Non-Small Cell Lung Cancer
    Lee, Tae Hoon
    Kang, Byung-Hee
    Kim, Hak Jae
    Wu, Hong-Gyun
    Lee, Joo Ho
    CANCER RESEARCH AND TREATMENT, 2023, 55 (03): : 865 - 874
  • [28] Post-progression survival after atezolizumab plus carboplatin and etoposide as first-line chemotherapy in small cell lung cancer has a significant impact on overall survival
    Masubuchi, Ken
    Imai, Hisao
    Wasamoto, Satoshi
    Tsuda, Takeshi
    Minemura, Hiroyuki
    Nagai, Yoshiaki
    Yamada, Yutaka
    Kishikawa, Takayuki
    Umeda, Yukihiro
    Shiono, Ayako
    Takechi, Hiroki
    Shiihara, Jun
    Kaira, Kyoichi
    Kanazawa, Kenya
    Taniguchi, Hirokazu
    Kaburagi, Takayuki
    Kagamu, Hiroshi
    Minato, Koichi
    THORACIC CANCER, 2022, 13 (19) : 2776 - 2785
  • [29] Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice
    Yamamoto, Takaya
    Tsukita, Yoko
    Katagiri, Yu
    Matsushita, Haruo
    Umezawa, Rei
    Ishikawa, Yojiro
    Takahashi, Noriyoshi
    Suzuki, Yu
    Takeda, Kazuya
    Miyauchi, Eisaku
    Saito, Ryota
    Katsuta, Yoshiyuki
    Kadoya, Noriyuki
    Jingu, Keiichi
    BMC CANCER, 2022, 22 (01)
  • [30] Efficacy and safety of recombinant human endostatin combined with radiotherapy or chemoradiotherapy in patients with locally advanced non-small cell lung cancer: a pooled analysis
    Zhang, Shu-Ling
    Han, Cheng-Bo
    Sun, Li
    Huang, Le-Tian
    Ma, Jie-Tao
    RADIATION ONCOLOGY, 2020, 15 (01)